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Tuberculosis control interventions targeted to previously 
treated people in a high-incidence setting: a modelling 
study
Florian M Marx*, Reza Yaesoubi*, Nicolas A Menzies, Joshua A Salomon, Alyssa Bilinski, Nulda Beyers, Ted Cohen
Summary
Background In high-incidence settings, recurrent disease among previously treated individuals contributes 
substantially to the burden of incident and prevalent tuberculosis. The extent to which interventions targeted to this 
high-risk group can improve tuberculosis control has not been established. We aimed to project the population-level 
effect of control interventions targeted to individuals with a history of previous tuberculosis treatment in a 
high-incidence setting.
Methods We developed a transmission-dynamic model of tuberculosis and HIV in a high-incidence setting with a 
population of roughly 40 000 people in suburban Cape Town, South Africa. The model was calibrated to data 
describing local demography, TB and HIV prevalence, TB case notifications and treatment outcomes using a Bayesian 
calibration approach. We projected the effect of annual targeted active case finding in all individuals who had 
previously completed tuberculosis treatment and targeted active case finding combined with lifelong secondary 
isoniazid preventive therapy. We estimated the effect of these targeted interventions on local tuberculosis incidence, 
prevalence, and mortality over a 10 year period (2016–25).
Findings We projected that, under current control efforts in this setting, the tuberculosis epidemic will remain in 
slow decline for at least the next decade. Additional interventions targeted to previously treated people could 
greatly accelerate these declines. We projected that annual targeted active case finding combined with secondary 
isoniazid preventive therapy in those who previously completed tuberculosis treatment would avert 
40% (95% uncertainty interval [UI] 21–56) of incident tuberculosis cases and 41% (16–55) of tuberculosis deaths 
occurring between 2016 and 2025.
Interpretation In this high-incidence setting, the use of targeted active case finding in combination with secondary 
isoniazid preventive therapy in previously treated individuals could accelerate decreases in tuberculosis morbidity 
and mortality. Studies to measure cost and resource implications are needed to establish the feasibility of this type of 
targeted approach for improving tuberculosis control in settings with high tuberculosis and HIV prevalence.
Funding National Institutes of Health, German Research Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Worldwide, an estimated 10·4 million people developed 
tuberculosis and 1·8 million deaths were attributable to 
the disease in 2015.1 Substantial innovation in 
tuberculosis control is needed to reach the targets of 
the new global End TB Strategy, which aims to eliminate 
the disease by the year 2035.2 The rates of tuberculosis 
decline must accelerate in settings with the highest 
disease incidence, some of which are located in 
southern Africa and are facing the dual burden of 
tuberculosis and HIV.3 In these settings, the prevalence 
of untreated tuberculosis remains high, and 
conventional control approaches that rely on passive 
case finding can fail to identify infectious cases early 
enough to prevent transmission.4–6
Active case finding and wide-scale use of preventive 
therapy have been considered as enhanced activities for 
improving tuberculosis control, but these approaches 
require substantial investment.7 Furthermore, dis-
appointing results from community-randomised trials 
of population-wide case finding and preventive therapy 
interventions8,9 have tempered enthusiasm for 
untargeted use of these interventions. It remains 
unknown whether targeting of case finding and 
preventive therapy to high-risk groups could be an 
effective approach for disease control in communities. 
The broader effect of a targeted approach depends on 
whether it is possible to prevent disease or reduce the 
duration of infectiousness among an easily identifiable 
subgroup that experiences a high relative risk of disease 
and is responsible for a substantial proportion of 
transmission.
One subgroup that might be attractive for targeted 
interventions is individuals with a history of previous 
tuberculosis treatment.10 Studies from southern Africa 
show a high incidence of recurrent tuberculosis even 
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after previous successful treatment,11–14 resulting from 
both endogenous reactivation and exogenous re-
infection.15 We recently documented a large burden of 
prevalent tuberculosis in previously treated adults in 
24 high tuberculosis burden communities in southern 
Africa, consistent with the hypothesis that this risk 
group drives a substantial proportion of transmission 
in these settings.16
In this study, we used a transmission-dynamic model 
to project the effect of two targeted control 
interventions—targeted active case finding and 
secondary isoniazid preventive therapy—in individuals 
who previously completed tuberculosis treatment in a 
high-incidence setting in suburban Cape Town, 
South Africa. We estimated the effect of these targeted 
interventions on tuberculosis incidence, prevalence, 
and mortality over a 10-year period.
Methods
Modelling approach
We developed a stochastic compartmental transmission-
dynamic model of the tuberculosis and HIV epidemic 
in a high-incidence setting of roughly 40 000 residents 
in suburban Cape Town, South Africa; the appendix 
pro vides details about the study setting. The 
tuberculosis component of our model followed the 
conventions of earlier models,17–21 with additional 
structure to distinguish between individuals who were 
never treated for tuberculosis (treatment-naive) and 
those who were previously treated for tuberculosis 
(treatment-experienced; figure 1).
We adopted previous ranges for parameters that 
allowed for differential partial immunity against re-
infection and differential reactivation rates in 
treatment-experienced and treatment-naive, latently 
infected individuals, and differential delay in detecting 
tuberculosis in individuals with and without history of 
tuberculosis treatment (table 1). We also allowed for 
higher infectiousness in treatment-experienced 
compared with treatment-naive tuberculosis cases, as 
suggested by local tuberculosis prevalence surveys that 
reported that treatment-experienced individuals with 
tuberculosis were more likely to report cough and more 
likely to be smear-positive than treatment-naive 
individuals without the disease.16 Among individuals 
with incomplete tuberculosis treatment, we assumed 
that up to 20% remained infectious, consistent with 
findings from a retrospective cohort study done in the 
study setting.26 Table 1 shows a list of key model 
parameters describing differences in treatment-naive 
and treatment-experienced individuals.
The HIV component of the model accounts for HIV 
infection, progression to a state of immunocompromised 
HIV infection, and antiretroviral treatment (ART; 
Research in context
Evidence before the study
Up to now, no empirical studies have been done of the 
population-level effect of interventions that aim to prevent 
recurrent disease or more rapidly detect tuberculosis in 
previously treated people. To establish whether 
population-based mathematical models have been employed to 
estimate the effect of tuberculosis interventions targeted to 
previously treated people, we did a PubMed search of relevant 
articles published in any language through March 7, 2017, using 
the search terms “(tuberculosis) AND (recurren* OR relapse OR 
reinfection OR re-infection OR re-treatment OR previous 
treatment) AND (model* OR simulation)”. We also reviewed 
titles and abstracts of mathematical modelling studies identified 
through an earlier comprehensive systematic literature review of 
studies describing mathematical and economic modelling of 
tuberculosis published through March 30, 2013 (conducted by 
Tuberculosis Modeling and Analysis Consortium [TB-MAC]). 
While mathematical models have considered the effect of 
improving treatment outcomes as a means of reducing relapse 
and associated transmission, none has addressed preferential 
targeting of tuberculosis control interventions to former 
tuberculosis patients.
Added value of this study
We developed a transmission-dynamic mathematical model 
of the tuberculosis epidemic and calibrated it to 
epidemiological and demographic data from a setting with a 
high incidence of tuberculosis in suburban Cape Town, 
South Africa. High rates of recurrent tuberculosis and a high 
prevalence of tuberculosis in previously treated people have 
previously been reported from this setting. We presented 
estimates of the potential effect of tuberculosis interventions 
targeted to people who completed an episode of tuberculosis 
treatment and noted that targeted prevention and case 
finding efforts could yield substantial benefits for tuberculosis 
control at the population level.
Implications of all the available evidence
Our results suggest substantial public health potential for 
control interventions targeted towards individuals with a 
history of previous tuberculosis treatment in settings with a 
high disease incidence. In these settings, previously treated 
people are especially attractive for targeted control 
interventions because they remain at an increased risk of active 
tuberculosis after apparent cure, contribute substantially to 
onward transmission, and should be readily identifiable by 
national tuberculosis programmes. Efforts to establish the 
feasibility and costs of such targeted interventions are needed 
to establish their cost-effectiveness in tuberculosis and HIV 
endemic settings.
See Online for appendix
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figure 1). We also implemented a model subcomponent 
for children aged 0–14 years. Additional model details 
including the subcomponent for children are described 
in the appendix.
Model initialisation and parameter estimation 
approach
We calibrated the model to data between 2002, and 2008; 
model simulations were initiated in 1992 to allow for a 
10-year burn-in period. We specified an initial 
population size of 32 889 (25 903 adults and 
10 427 children aged 0–14 years), informed by local 
census data and projections of population growth. The 
values of many parameters in tuberculosis and HIV 
co-epidemics models are not known with certainty. 
Therefore, we adopted a Bayesian calibration approach27 
to identify parameter sets that resulted in simulated 
trajectories with good fit to available epidemiological 
data (table 2). To implement this approach, we specified 
previous distributions for each parameter. Multiple 
parameters sets were randomly and independently 
selected from these distributions. We used each of 
these parameter sets to simulate epidemic trajectories, 
and measured the goodness-of-fit for each of these 
simulations against several calibration targets. These 
calibration targets were operationalised as the 
likelihood of recording the epidemiological data 
conditional on the simulated values. The appendix 
provides additional details about the likelihood function 
used and the methods to characterise the posterior 
parameter distributions. Figure 2 displays the fit of 
simulated trajectories against the calibration targets 
listed in table 2.
Interventions
We used the model to project the effect of two targeted 
interventions: targeted active tuberculosis case finding 
and secondary isoniazid preventive therapy. For 
Figure 1: Structure of the mathematical model
Dashed arrows are modelled interventions, 2°IPT=secondary isoniazid preventive therapy. TACF=targeted active case finding. Mortality rates are not shown. The 
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targeted active case finding we assumed that all adults 
who previously completed tuberculosis treatment were 
re-evaluated for active tuberculosis on average once per 
year and referred for tuberculosis treatment. We 
modelled targeted active case finding by increasing the 
rate of diagnosis, resulting in reductions in the average 
diagnostic delay, and the expected period of 
infectiousness (figure 1).
For secondary isoniazid preventive therapy, in the 
first year of intervention, we modelled a catch-up 
treatment campaign that reached 90% of individuals 
with previously completed tuberculosis treatment in 
the population. Subsequent to this catch-up period, we 
assumed that secondary isoniazid preventive therapy 
was offered to individuals after the completion of a full 
course of tuberculosis treatment and that an average of 
90% of individuals completing treatment were enrolled. 
Secondary isoniazid preventive therapy reduces the rate 
of tuberculosis re activation and the risk of progression 




Relative infectiousness of treatment-experienced vs 
treatment-naive adults with active tuberculosis (ratio)
1·000 to 1·500 Assumption, based on findings from Marx et al16
Percentage reduction in susceptibility due to partial immunity (HIV-negative adults)
During latent tuberculosis infection (tuberculosis 
treatment-naive)
0·370 to 0·870 Menzies et al,20 Dye and Williams,22 Dye and Espinal,23 Cohen et al,24 Dowdy 
and Chaisson25
After complete tuberculosis treatment 0·370 to 0·870 Assumption
After incomplete tuberculosis treatment 0·370 to 0·870 Assumption
Annual rate of tuberculosis reactivation (HIV-negative adults)
Latent infection 0·0003 to 0·0024 Menzies et al,20 Dye and Williams,22 Dye and Espinal,23 Cohen et al,24 
Dowdy and Chaisson25
Previously treated active tuberculosis 0·0003 to 0·048 Assumption
Baseline time (years) between onset of tuberculosis and detection (adults, independent of tuberculosis treatment history)
Treatment-naive, HIV-negative adults and children 0·083 to 3·000 Menzies et al,20 Dye and Williams,22 Dye and Espinal,23 Cohen et al,24 
Dowdy and Chaisson25
Treatment-experienced, HIV-negative adults 0·083 to 2·000 Assumption
HIV-positive adults 0·083 to 2·000 Assumption
Percentage tuberculosis treatment completion
Treatment-naive adults Time-varying Estimated from tuberculosis treatment register database used in Marx et al.14
Adults after previous complete tuberculosis treatment Time-varying ..
Adults after previous incomplete tuberculosis treatment Time-varying ..
Probability of persistent active tuberculosis following 
incomplete tuberculosis treatment (adults, any HIV status)
0 to 0·200 Based on data from Marx et al26






Adults 25 903 ·· City of Cape Town*
Children 10 427 ·· City of Cape Town
Percentage tuberculosis treatment-experienced adults (2002) 9·70 8·70–10·90 den Boon et al28
Percentage tuberculosis prevalence, treatment-naïve adults (2002) 0·51 0·26–0·76 den Boon et al28
Percentage tuberculosis prevalence, treatment-experienced adults 
(2002)
2·99 1·14–4·77 den Boon et al28
Percentage HIV prevalence, adults (2002) 5·20 ·· Assumption, based on data from Western Cape 
Department of Health29
Number of children who started tuberculosis treatment (2002–08) Time-varying ·· Tuberculosis treatment register database used in Marx et al.14
Number of treatment-naive adults who started tuberculosis 
treatment (2002–08)
Time-varying ·· Tuberculosis treatment register database used in Marx et al.14
Number of treatment-experienced adults who started tuberculosis 
treatment (2002–08)
Time-varying ·· Tuberculosis treatment register database used in Marx et al.14
*Unpublished end-of-year estimates (community level) from the 2001 South Africa population census provided by the City of Cape Town.
Table 2: Overview of calibration targets and data sources
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preventive effects of secondary isoniazid preventive 
therapy to vary between 45% and 85%, a range informed 
by two previous studies.30,31 We assumed that the relative 
effect of secondary isoniazid preventive therapy was 
independent of HIV infection, but the absolute effect 
associated with this intervention remains greater for 
those with HIV in view of their higher reactivation rate 
and risk of progression.
Secondary isoniazid preventive therapy was intended 
as a lifelong intervention but we assumed that, on 
average, 15% of people currently on secondary isoniazid 
preventive therapy drop out every year (resulting in an 
expected duration of 6·6 years of secondary isoniazid 
preventive therapy), and that the protective effect of 
secondary isoniazid preventive therapy does not extend 
beyond the cessation of treatment.32
Model outcomes and data analysis
We projected trends in tuberculosis incidence, pre-
valence, and mortality for 10 consecutive years—ie, 
2016–25, under the baseline scenario and under 
two interventions scenarios: targeted active case finding 
alone and targeted active case finding plus secondary 
isoniazid preventive therapy. The effect of these 
interventions was defined as the cumulative number of 
tuberculosis cases and deaths averted during the 10-year 
period relative to the baseline scenario. The results are 
presented as the mean and 95% uncertainty intervals 
(the 2·5th and 97·5th percentiles of outcome values 
derived from 1000 simulated trajectories).
Sensitivity and scenario analyses
To assess how sensitive the projected effect of targeted 
active case finding and secondary isoniazid preventive 
therapy was to input parameters of our model, we 
calculated partial rank correlation coefficients.33,34 The 
coefficients measure the correlation between an input 
parameter and the projected model outcome (number 
of incident tuberculosis cases averted) while adjusting 
for other parameters in the model. Additionally, we did 
the following types of scenario analyses: the projected 
effect of both targeted interventions under different 
periodicities of targeted active case finding (every 6 vs 
12 and 24 months on average), different probabilities 
of secondary isoniazid preventive therapy enrolment 
(none vs 50%, 75%, and 90%), and different annual 
rates of drop-out from secondary isoniazid preventive 
therapy (5% vs 15% and 25%) were assessed. 
Furthermore, to provide additional insight on how well 






















































































































































Tuberculosis case notifications, children
Children
Treatment-experienced adults Treatment-naive adults Treatment-experienced adults
Adults HIV prevalence, adults
Tuberculosis case notifications, 
treatment-naive adults
Tuberculosis case notifications, 
treatment-experienced adults
Figure 2: Calibration targets and fitted model trajectories
Green dots denote the nine calibration targets, with error bars representing 95% CIs where applicable; grey lines represent 100 simulated trajectories produced by the 
calibrated model; the simulated trajectories that fell outside the feasible regions (shaded areas) were considered extremely unlikely and were eliminated by the 
calibration method. The interval between the dashed vertical lines shows the model calibration period (2002–08).
Articles
e431 www.thelancet.com/lancetgh   Vol 6  April 2018
communities with lower transmission rates, we report 
results for a hypothetical scenario where we reduced 
the force of infection by 50% relative to that in our 
study setting.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all of the data and the final responsibility 
to submit for publication.
Results
We estimated that in 2016, 13% (95% uncertainty 
interval [UI] 11–16) of all adults in this population had 
previously been treated for active tuberculosis. The 
estimated prevalence of untreated tuberculosis was 
2·2% (95% UI 0·9–3·8) in treatment-experienced 
adults, about 5·5 times higher than that in treatment-
naive adults (0·4%, 0·1–0·8).
The identified parameter posterior distributions sug-
gested that HIV uninfected treatment-experienced 
people were, on average, 1·6 times (95% UI 0·4–3·4) 
more susceptible to re-infection than were HIV 
uninfected people who were latently infected and 
tuberculosis treatment-naive. HIV uninfected adults 
who had comp leted tuberculosis treatment experienced, 
on average, a 35 times (95% UI 3·2–104·0) higher rate 
of tuberculosis reactivation than people who were 
latently infected and tuberculosis treatment-naive. The 
appendix provides posterior distributions of key 
parameters of the natural history of tuberculosis for 
treatment-experienced and treatment-naive individuals.
In the absence of targeted interventions, we projected 
4457 (95% UI 2741–6723) incident tuberculosis cases 
and 623 (328–1031) tuberculosis-associated deaths 
between 2016 and 2025. In this period, 1423 (95% UI 
670–22 311) incident tuberculosis cases will occur 
among adults who had completed a prior episode of 
treatment, representing 32% (20–39) of all incident 
cases.
Figure 3 shows trends in tuberculosis incidence 
projected for treatment-naive and treatment-
experienced adults over a 25-year period. Among 
treatment-naive adults, mean tuberculosis incidence 
per 100 000 people was 903 (95% UI 541–1147) 
in 2016 and was projected to decrease to 787 (287–1020) 
by 2025 (figure 3). Mean tuberculosis incidence among 
treatment-experienced adults was 4926 (95% UI 
2949–6857) per 100 000 people in 2016, 5·5-times higher 
than among treatment-naive adults, and is expected to 
fall to 4353 (1874–5917) by 2025. The projected average 
annual decrease in tuberculosis incidence between 
2016 and 2025 was 1·3% in treatment-naive and 1·2% in 
treatment-experienced adults.
With regards to the epidemiological effect of the 
interventions, our model suggests that annual targeted 
active case finding among individuals who had 
completed tuberculosis treatment would reduce the 
average duration of infectious disease in this group 
from 9·7 months (95% UI 2·3–17·5) to 5·0 months 
(1·9–7·1).
Figure 4 shows trends in tuberculosis incidence, 
prevalence, and mortality under the baseline scenario, 
under targeted active case finding alone, and under 
combined targeted active case finding and secondary 
isoniazid preventive therapy. The average annual 
decline in tuberculosis incidence between 2016 and 2025 
relative to 2015 was 1·6% at baseline (no intervention), 
3·0% under annual targeted active case finding, and 
5·4% under annual targeted active case finding in 
combination with secondary isoniazid preventive 
therapy. Targeted active case finding alone would avert 
a total of 621 (95% UI 13–1355) incident tuberculosis 
cases between 2016 and 2025, 14% (0·4–28·0) of all 
incident tuberculosis cases projected under the baseline 
scenario. Over the same time period, targeted active 
case finding would avert a total of 138 (95% UI 13–296) 
tuberculosis deaths, 21% (2·5–39·0) of all tuberculosis 
deaths projected under the baseline scenario. The 
Figure 3: Tuberculosis incidence among treatment-naive and 
treatment-experienced adults between 2003 and 2025, projected under 
the baseline scenario
Mean estimates (bold red line) represent the mean prediction at any given year. 
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implementation of targeted active case finding in 
combination with secondary isoniazid preventive 
therapy would avert 1805 (95% UI 565–2952) incident 
tuberculosis cases between 2016 and 2025, 40% (21–56) 
of all incident tuberculosis cases projected under the 
baseline scenario. The combined targeted intervention 
would avert a total of 267 (95% UI 70–543) tuberculosis 
deaths, 41% (16–55) of all tuberculosis deaths projected 
under the baseline scenario.
Findings of sensitivity analysis showed that the 
projected effect of targeted active case finding and 
secondary isoniazid preventive therapy was most sensitive 
to the tuberculosis reactivation rate after completion of 
tuberculosis treatment, the time between tuberculosis 
disease onset and detection in the target group, the 
natural mortality rate in treatment-experienced relative to 
treatment-naive adults, and the efficacy of secondary 
isoniazid preventive therapy, among other parameters 
(appendix p 18). Lower periodicity of targeted active case 
finding (every 24 vs 12 months) and lower uptake of 
secondary isoniazid preventive therapy, as well as higher 
drop-out from secondary isoniazid preventive therapy, 
resulted in reduced effect (appendix p 19). In a 
hypothetical scenario in which we reduced the force of 
infection to 50% of the baseline value, we noted that 
annual targeted active case finding in combination 
with secondary isoniazid preventive therapy averted 
34% (95% UI 16–54) of 2811 (1742–4503) incident 
tuberculosis cases and 36% (14–56) of 444 (231–760) 
tuberculosis deaths estimated at baseline (appendix p 19).
Discussion
In this study, we used a calibrated population-based 
mathematical model to project the effect of two types of 
interventions targeted to previously treated people in a 
tuberculosis high-incidence setting. Our data suggest that, 
if targeted active case finding and secondary isoniazid 
preventive therapy were introduced to complement 
existing tuberculosis control efforts in this setting, the 
burden of tuberculosis could be substantially reduced. 
Our study supports the idea that efforts for prevention and 
prompt detection of recurrent tuberculosis35 could offer 
novel opportunities for tuberculosis control in settings of 
high tuberculosis incidence.
We propose these targeted control interventions during 
a time when untargeted efforts, such as population-wide 
enhanced case finding and household-based screening8 
and mass isoniazid preventive therapy9 have yielded 
insufficient evidence of effect, and where novel 
approaches are urgently needed to reduce the burden of 
tuberculosis in communities most affected by the 
disease. Targeting control efforts to groups at high risk 
of tuberculosis could enable health services to make 
more efficient use of available resources. In many 
high tuberculosis prevalence settings, previously treated 
people can be easily identified and experience an elevated 
risk of tuberculosis,16 therefore they might be an attractive 
target for focused interventions.
We project that within 10 years in this setting, a 
combination of targeted active case finding and 
secondary isoniazid preventive therapy could avert 
more than a third of incident tuberculosis cases and 
tuberculosis deaths. Targeted active case finding alone 
could have a notable effect on tuberculosis prevalence 
and mortality, but is expected to have a smaller effect on 
incidence; our simulations suggest that a marked effect 
of targeted active case finding is achieved when it can 
be coupled with secondary isoniazid preventive therapy. 
Our projections show that much of the effect of targeted 
active case finding and secondary isoniazid preventive 
therapy accrues in the first few years after their 
implementation. The diminishing effect over time 
suggests a saturation effect, which might imply that 
such targeted interventions could be used within an 
adaptive control strategy.21
Our study constitutes a first step towards better 
understanding the effect of interventions targeted to 
previously treated people in high-incidence settings. 
Figure 4: Projected epidemiological effect of interventions targeted to individuals with a history of previous complete tuberculosis treatment in a 












































Tuberculosis incidence Tuberculosis prevalence Tuberculosis mortality
No targeted intervention Targeted active case finding (annually) Targeted active case finding (annually) + secondary isoniazid 
preventive therapy
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However, several limitations must be noted. We applied 
our model to a specific setting with a high tuberculosis 
incidence and where high rates of recurrent tuberculosis 
due to relapse and re-infection had been previously 
reported.12,14,36 We note that the effect of interventions 
targeted at previously treated people, which we project 
for this setting, might not be easily generalised to other 
high-incidence settings for several reasons. High rates of 
recurrent tuberculosis have been reported from several 
other high-incidence settings.10,11,13 However, the 
population-level effect of targeted interventions will 
also depend on the size of the target group and 
their contribution to tuberculosis transmission in 
the population. In this particular setting, persistently 
high rates of incident tuberculosis have generated a large 
subgroup of people who had previously been treated for 
tuberculosis (about 10% of all adults) and who constitute 
a substantial proportion of the prevalent tuberculosis 
burden in the population (about 30% of prevalent cases).
Although our projections are consistent with the 
epidemiology of tuberculosis in other high-incidence 
communities in South Africa,5,16 we expect interventions 
among previously treated people to be less effective in 
settings with lower tuberculosis incidence, and where a 
smaller proportion of the tuberculosis burden is 
attributable to former tuberculosis patients. For example, 
previously treated people accounted for 4·1% of the adult 
population and for 13% of prevalent tuberculosis cases in 
Lusaka, Zambia,6 and for 1·5% and 15%, respectively, in 
Nigeria37—two settings with lower tuberculosis incidence 
than our study setting. Nonetheless, given that new 
approaches for tuberculosis control are most needed in 
areas where tuberculosis incidence has been persistently 
high, our results suggest that efforts to both prevent and 
rapidly detect and treat recurrent disease will produce 
important health benefits. In our scenario analysis, 
for which we lowered the force of infection by 50%, we 
noted that targeted active case finding in combination with 
secondary isoniazid preventive therapy reduced the 
expected number of incident tuberculosis cases and deaths 
to a lesser extent, but still averted a third of incident cases.
Differences in the prevalence of HIV in a population 
might influence the effect of interventions targeted to 
previously treated people in several ways. Communities 
with higher HIV prevalence might experience more 
recurrent tuberculosis given the elevated risk of re-
infection with tuberculosis among HIV-infected 
individuals,38 and thus benefit more from similar 
interventions. Survival after a first tuberculosis episode 
might be reduced among those not on ART; those on 
ART may be subject to more regular clinical follow-up 
that would limit the benefit of additional case finding 
interventions in this group.
The population-level effect of targeted active case finding 
and secondary isoniazid preventive therapy will be 
dependent upon existing patterns of passive health-care 
seeking behaviour. In settings where there are longer 
delays to diagnosis, additional interventions to more 
rapidly identify and treat recurrent cases would be more 
effectual, whereas in areas where individuals self-present 
quickly after onset of symptoms, we would expect more 
modest returns from investment in combined targeted 
active case finding and secondary isoniazid preventive 
therapy interventions. This is consistent with our 
sensitivity analysis, which showed that the time to passive 
tuberculosis detection among treatment-experienced 
adults correlated with the projected effect.
Uncertainty around parameters of the natural history 
of tuberculosis, particularly those determining re-
infection, disease progression, and mortality among 
previously treated individuals, leads to substantial 
uncertainty in the modelled outcomes. To avoid bias 
towards higher estimates of effect, we used conservative 
prior ranges of parameters for treatment-experienced 
adults, similar to those among treatment-naive adults. 
Specifically, we did not enforce higher susceptibility, 
lower partial immunity, or higher disease progression 
risk among those with a history of previous tuberculosis, 
but did allow posterior parameter values derived from 
calibration to vary by treatment history. While posterior 
distributions of our model are consistent with 
treatment-experienced people being more likely to 
become productively re-infected than treatment-naive 
people, we did not explicitly model differential risk of 
exposure, which could also be a mechanism driving 
increased risk of recurrent disease.39
Our study is further limited by uncertainty around 
the efficacy of secondary isoniazid preventive therapy 
towards preventing recurrent tuberculosis. As shown 
in our sensitivity analysis, higher effects of secondary 
isoniazid preventive therapy would result in higher 
effect at the population level. Only two studies—a 
randomised trial30 and a cohort study31—have assessed 
the effect of preventive therapy on recurrent 
tuberculosis. Both were limited in size and focused on 
people living with HIV. More available data from the 
field would improve our projections.
We used a simple mathematical model that does not 
enable us to explore specific intervention designs or 
consider many practical issues related to implementation. 
In particular, in our main analysis we assumed that 
interventions could be aggressively rolled out in these 
suburban settings—ie, that individuals with previous 
treatment could be effectively identified, enrolled, and 
screened for tuberculosis on average every 12 months, 
that 90% could be enrolled in secondary isoniazid 
preventive therapy upon completing treatment, and 
15% would drop out from secondary isoniazid preventive 
therapy every year. Although we believe high coverage 
levels of the interventions could be achieved in this 
relatively small suburban setting, the effect of these 
interventions would clearly be lower if interventions 
were less vigorously applied or if some individuals were 
not reachable by the intervention.
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In conclusion, our study provides impetus for further 
research to better understand the individual and 
population-level benefits of tuberculosis control 
interventions targeted at previously treated people. 
Studies and trials of the feasibility, safety, effect, and 
population-level effect of targeted active case finding and 
secondary isoniazid preventive therapy in previously 
treated people in high-incidence settings would be 
particularly useful. Other interventions to prevent 
recurrent tuberculosis such as adjuvant immunotherapy 
during tuberculosis treatment,40 extending the duration of 
tuberculosis treatment for certain high-risk patients,34 or 
post-treatment vaccination might be considered in the 
future. Further mathematical modelling, in which 
detailed costs of interventions are also included, would be 
useful for policy makers as they could establish whether 
such interventions are cost-effective and how investment 
in these approaches may compare with alternatives.
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